The ADHD market is highly genericized, and prescriptions for generic products constitute the vast majority of market volume. Very few branded drugs are available outside of the US. Most ADHD medications are oral, once daily, and approved for those aged six years and above. There is a global shortage of ADHD treatments currently, particularly generic methylphenidate and amphetamine formulations, which is expected to continue into mid-2024. 

Stimulants (various formulations of methylphenidate and amphetamine) dominate the ADHD market and are the current standard of care due to their high efficacy levels. The downside of stimulants are their safety profiles, while they also have high abuse potential and are consequently classified as Schedule II drugs, which can cause difficulties with insurance coverage and market access. 

This Datamonitor Healthcare report contains a Disease Analysis module.